While the clinical characteristics of ALK-fusion gastrointestinal tumors have been previously documented, there is a dearth of data regarding the efficacy of ALKi in patients with ALK-positive CRC due to its rarity in colorectal malignancies. This evidence concerns the gene ALK and colorectal carcinoma.